Sugi Predict

Sugi Predict / Compounds / SCHEMBL6575843

SCHEMBL6575843

SCHEMBL6575843

CCOC(=O)C(O)CN(C(=O)OCc1ccccc1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ HPGD P15428 1/20 0.44
▸ LMNA P02545 2/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ ABCB1 P08183 1/20 0.41
▸ MMP8 P22894 1/20 0.40
▸ GLA P06280 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ TP53 P04637 1/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28459939 0.80 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2MAPTHPGDL3MBTL1
SCHEMBL11063095 0.79 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2MAPTHPGDLMNA
SCHEMBL3084308 0.77 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2MAPTHPGDL3MBTL1
SCHEMBL27693262 0.76 SMN1; SMN2 (0.51) ALDH1A1SMN1; SMN2MAPTHPGDLMNA
SCHEMBL1782358 0.75 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2MAPTHPGDL3MBTL1
SCHEMBL11065640 0.75 ALDH1A1 (0.43) ALDH1A1MAPTHPGDLMNAL3MBTL1
SCHEMBL11062234 0.75 ALDH1A1 (0.43) ALDH1A1MAPTHPGDLMNAL3MBTL1
SCHEMBL6980622 0.75 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MAPTHPGDLMNA
SCHEMBL2516270 0.75 L3MBTL1 (0.52) ALDH1A1SMN1; SMN2LMNAL3MBTL1HSD17B10
SCHEMBL2516271 0.75 L3MBTL1 (0.52) ALDH1A1SMN1; SMN2LMNAL3MBTL1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1547567-A Chiral resolution method for producing compounds useful in the synthesis of taxanes ���׿ƹɷ����޹�˾ 2004-11-17 — — CN disclosed
EP-1412319-A1 CHIRAL RESOLUTION METHOD FOR PRODUCING COMPOUNDS USEFUL IN THE SYNTHESIS OF TAXANES NAPRO BIOTHERAPEUTICS, INC. (US) 2004-04-28 — — EP disclosed
US-6653501-B2 Using chromatographic process for separating a target chiral compound from its enantiomer in a racemic mixtures; purification NAPRO BIOTHERAPEUTICS, INC. 2003-11-25 — — US disclosed
US-20030045743-A1 Chiral resolution method for producing compounds useful in the synthesis of taxanes MAYNE PHARMA (USA), INC. 2003-03-06 — — US disclosed
WO-2003002509-A1 CHIRAL RESOLUTION METHOD FOR PRODUCING COMPOUNDS USEFUL IN THE SYNTHESIS OF TAXANES NAPRO BIOTHERAPEUTICS, INC. (US) 2003-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045743-A1 Chiral resolution method for producing compounds useful in the synthesis of taxanes CCNK, OPRK1, SYMPK ALDH1A1 3529/4885SMN1; SMN2 1390/4885MAPT 2238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.